Clinical Trials Directory

Trials / Completed

CompletedNCT07110740

Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects

A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Evaluate Bioequivalence After Dry-powder Inhalation of UIC202005 or UI009 in Healty Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Korea United Pharm. Inc. · Industry
Sex
All
Age
19 Years
Healthy volunteers
Accepted

Summary

A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Evaluate Bioequivalence After Dry-powder Inhalation of UIC202005 or UI009 in Healty Volunteers

Conditions

Interventions

TypeNameDescription
DRUGUI009inhale UI009 twice a day on Day 1 and Day 8.
DRUGUIC202005inhale UIC202005 twice a day on Day 1 and Day 8.

Timeline

Start date
2024-10-24
Primary completion
2024-11-29
Completion
2024-12-13
First posted
2025-08-08
Last updated
2025-08-08

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT07110740. Inclusion in this directory is not an endorsement.

Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects (NCT07110740) · Clinical Trials Directory